Code Pharma, a pioneering pharmaceutical company headquartered in the Netherlands, is set to present groundbreaking findings from its clinical trials on GAMMORA, a drug aimed at treating HIV, at two prestigious events later this year.
The first presentation will take place in November 2024 at the HIV Drug Therapy 2024 Conference in Glasgow, Scotland. During this event, Code Pharma will unveil promising early-stage results from clinical trials, highlighting GAMMORA’s unique approach and its potential to reshape HIV treatment.
In December 2024, the spotlight will shift to the HIV Persistence During Therapy Workshop in Miami, Florida, where Code Pharma will emphasize the drug’s potential to revolutionize HIV treatment by targeting the virus in ways not previously seen in existing therapies.
GAMMORA, developed by Code Pharma, represents a breakthrough in the fight against HIV. This innovative drug takes a novel approach by targeting and eliminating HIV-infected cells. Unlike traditional antiretroviral therapies, which focus on controlling the virus by delaying its viral activities, GAMMORA works by inducing the self-destruction of HIV-infected cells, allowing the immune system to regenerate healthy CD4 cells.
Early clinical trials have shown promising results, with GAMMORA drastically reducing the HIV viral load without causing harmful side effects. Its precision targeting ensures that only infected cells are eliminated, leaving healthy cells intact. The drug’s synthetic peptide, derived from HIV-1 integrase, was initially identified at the Hebrew University of Jerusalem, Israel. By inducing the viral integration process, GAMMORA pushes HIV-infected cells into self-destruction, offering the potential for a cure rather than the lifelong management of HIV as a chronic condition.
Code Pharma is a leading global pharmaceutical company with substantial R&D operations in Israel. The company specializes in the development of cost-effective, peptide-based treatments for infectious diseases and cancer. Through collaboration with an international team of experts in peptide chemistry, cell culture, and clinical development, Code Pharma is committed to delivering groundbreaking therapies that address unmet medical needs, with the ultimate goal of transforming patient outcomes worldwide.
“We are excited to present the promising results of our clinical trials for GAMMORA at these two prestigious events,” said Dr. John Smith, CEO of Code Pharma. “We believe that this drug has the potential to revolutionize HIV treatment and improve the lives of millions of people living with the virus.”
For more information about Code Pharma, GAMMORA, or upcoming events, please visit https://www.codepharma.com/ or email us at info@codepharma.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.